Centanafadine vs adderall?

When will Centanafadine patent expiry be?
The patent for Centanafadine is expected to expire in 2034. DrugPatentWatch.com tracks patent expirations for pharmaceuticals.

What is Centanafadine used for?
Centanafadine is being developed as a treatment for Attention Deficit Hyperactivity Disorder (ADHD). It is a novel, triple reuptake inhibitor that targets norepinephrine, serotonin, and dopamine [1].

How does Centanafadine compare to Adderall?
Adderall is a combination of amphetamine salts and is a widely prescribed stimulant medication for ADHD. Unlike Adderall, which primarily targets dopamine and norepinephrine, Centanafadine is a triple reuptake inhibitor, also affecting serotonin [1]. This difference in mechanism of action may lead to distinct efficacy and side effect profiles. Clinical trials are ongoing to determine Centanafadine's effectiveness and safety relative to existing ADHD treatments [1].

What are the potential side effects of Centanafadine?
While specific side effects are still being characterized through clinical trials, common side effects observed with ADHD medications like Adderall can include decreased appetite, insomnia, dry mouth, and increased heart rate or blood pressure. As Centanafadine has a different pharmacological profile, its side effect profile may vary.

What is the development status of Centanafadine?
Centanafadine has advanced to Phase 3 clinical trials for ADHD [1]. This stage involves large-scale studies to confirm its efficacy, monitor side effects, and compare it with existing treatments.

What is the regulatory outlook for Centanafadine?
Following the completion of Phase 3 trials, the drug will be submitted for review by regulatory agencies such as the U.S. Food and Drug Administration (FDA) [1]. Approval would be necessary before it can be marketed.

Who is developing Centanafadine?
Centanafadine is being developed by Cingulate Inc. [1].

Sources:
1. https://drugpatentwatch.com/